CCM
CHRS icon

Coldstream Capital Management’s Coherus Oncology CHRS Stock Holding History

Coldstream Capital Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-850
Closed -$686 – 1543
2025
Q1 		$686 Buy
+850
New +$978 ﹤0.01% 3268

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Coldstream Capital Management's CHRS Position: Q2 2025 in Review

Coldstream Capital Management sold out of Coherus Oncology (CHRS) in Q2 2025, closing a stake of 850 shares — an estimated $686 sold.

Coldstream Capital Management first reported a position in CHRS in Q1 2025 and held it in 1 quarter. The position peaked at $686 in Q1 2025. 112 funds tracked by Wall St. Rank hold CHRS as of Q2 2025.

  • Coldstream Capital Management reported no remaining Coherus Oncology position as of Q2 2025 after selling out during the quarter.
  • Coldstream Capital Management sold 850 Coherus Oncology shares in Q2 2025, an estimated $686.
  • Coldstream Capital Management first reported a position in Coherus Oncology in Q1 2025 and held it in 1 quarter.
  • Coldstream Capital Management's Coherus Oncology position peaked at $686 in Q1 2025.
  • 112 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2025.

Based on Coldstream Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.